Journal of the American Academy of Dermatology · 2024
Evaluating cancer risk in a large cohort of 25,008 patients with vitiligo: Insights from a comprehensive cohort population-based study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schonmann Yochai, Cohen Naama T, Czarnowicki Tali
Аннотация
BACKGROUND: Current research presents inconsistent results concerning the incidence of various malignancies among patients with vitiligo.
OBJECTIVES: To evaluate the risk of cancer in patients with vitiligo.
METHODS: A population-based study was conducted using Clalit Health Services database (2000-2023) using a cohort study design. Adjusted hazard ratios (HRs) were calculated using multivariate Cox regressions.
RESULTS: The study included 25,008 patients with vitiligo and 245,550 matched controls. The mean (SD) age of patients with vitiligo was 35.96 (22.39) years; 12,679 (50.70%) patients were men. There were 499 (95% confidence interval [CI]: 468-532) and 487 (95% CI: 476-497) incident cancer cases per 100,000 person-years among patients with and without vitiligo, respectively (adjusted HR: 1.00; 95% CI: 0.93-1.07; P = .999). Patients with vitiligo had a reduced risk of melanoma (adjusted HR: 0.70; 95% CI: 0.50-0.99; P = .0337), lung cancer (adjusted HR: 0.73; 95% CI: 0.57-0.93; P = .007), and bladder cancer (adjusted HR: 0.70; 95% CI: 0.52-0.94; P = .0138).
LIMITATIONS: The secondary analysis involved multiple comparisons, which could potentially influence the results.
CONCLUSION: Our study found that cancer incidence rates in patients with vitiligo are not elevated. Consequently, cancer screening for these patients should follow the standard guidelines recommended for the general population.
OBJECTIVES: To evaluate the risk of cancer in patients with vitiligo.
METHODS: A population-based study was conducted using Clalit Health Services database (2000-2023) using a cohort study design. Adjusted hazard ratios (HRs) were calculated using multivariate Cox regressions.
RESULTS: The study included 25,008 patients with vitiligo and 245,550 matched controls. The mean (SD) age of patients with vitiligo was 35.96 (22.39) years; 12,679 (50.70%) patients were men. There were 499 (95% confidence interval [CI]: 468-532) and 487 (95% CI: 476-497) incident cancer cases per 100,000 person-years among patients with and without vitiligo, respectively (adjusted HR: 1.00; 95% CI: 0.93-1.07; P = .999). Patients with vitiligo had a reduced risk of melanoma (adjusted HR: 0.70; 95% CI: 0.50-0.99; P = .0337), lung cancer (adjusted HR: 0.73; 95% CI: 0.57-0.93; P = .007), and bladder cancer (adjusted HR: 0.70; 95% CI: 0.52-0.94; P = .0138).
LIMITATIONS: The secondary analysis involved multiple comparisons, which could potentially influence the results.
CONCLUSION: Our study found that cancer incidence rates in patients with vitiligo are not elevated. Consequently, cancer screening for these patients should follow the standard guidelines recommended for the general population.